Alleviating anastrozole induced bone toxicity by selenium nanoparticles in SD rats

Toxicology and Applied Pharmacology

Volumn 268, Issue 2, 2013, Pages 212-220

  Vekariya, Kiritkumar K ^a   Kaur, Jasmine ^a   Tikoo, Kulbhushan ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Anastrozole; Osteoporosis; Selenium nanoparticles

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ANASTROZOLE; ESTROGEN; NANOPARTICLE; SELENIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BONE DENSITY; BONE DISEASE; BONE TOXICITY; BONE TURNOVER; CALCIFICATION; CELL DEATH; CONCENTRATION (PARAMETERS); CONJUGATION; CONTROLLED STUDY; ENZYME ACTIVITY; ESTROGEN DEFICIENCY; FEMALE; FEMUR; HISTOPATHOLOGIC SKIN REACTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MINERALIZATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; RAT; TOXICITY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ALKALINE PHOSPHATASE; ANIMALS; AROMATASE INHIBITORS; BONE AND BONES; CELLS, CULTURED; FEMALE; HUMANS; NANOPARTICLES; NITRILES; OSTEOBLASTS; OSTEOPOROSIS; RATS; RATS, SPRAGUE-DAWLEY; SELENIUM; TRIAZOLES;

EID: 84875065269     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.01.028     Document Type: Article

References (28)

1. Abbott L., et al. Acid phosphatase. Clinical Chemistry 1984, 1079-1083. The C. V. Mosby, St. Louis, Mo, USA. A. Kaplan (Ed.).
2. Arjmandi B.H., Alekel L., Hollis B.W., Amin D., Stacewicz-Sapuntzakis M., Guo P., Kukreja S.C. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J. Nutr. 1996, 126:161-167.
3. Body J.J. Management of primary osteoporosis. Acta Clin. Belg. 2002, 57:276-282.
4. Buzdar A.U., Robertson J.F.R., Eiermann W., Nabholtz J.M. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002, 95:2006-2016.
5. Chen Y.C., Sosnoski D.M., Gandhi U.H., Novinger L.J., Prabhu K.S., Mastro A.M. Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer. Carcinogenesis 2009, 30:1941-1948.
6. Chung Y.W., Kim T.S., Lee S.Y., Lee S.H., Choi Y., Kim N., Min B.M., Jeong D.W., Kim I.Y. Selenite-induced apoptosis of osteoclasts mediated by the mitochondrial pathway. Toxicol. Lett. 2006, 160:143-150.
7. Ebert R., Jakob F. Selenium deficiency as a putative risk factor for osteoporosis. Int. Congr. Ser. 2007, 1297:158-164.
8. Foster P.A., Chander S.K., Newman S.P., Woo L.W., Sutcliffe O.B., Bubert C., Zhou D., Chen S., Potter B.V.L., Reed M.J. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor. Clin. Cancer Res. 2008, 14:6469-6477.
9. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 2003, 349:1793-1802.
10. Howell A. Effect of anastrozole on bone mineral density: 2-year results of the 'arimidex'(anastrozole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res. Treat. 2003, 82:S27.
11. Järhult J. Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism. Breast Cancer 2011, 1-3.
12. Kalu D.N., Liu C.C., Salerno E., Hollis B., Echon R., Ray M. Skeletal response of ovariectomized rats to low and high doses of 17 [beta]-estradiol* 1. Bone Miner. 1991, 14:175-187.
13. Lean J.M., Davies J.T., Fuller K., Jagger C.J., Kirstein B., Partington G.A., Urry Z.L., Chambers T.J. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J. Clin. Invest. 2003, 112:915-923.
14. Lipton A. Management of metastatic bone disease and hypercalcemia of malignancy. Am. J. Cancer 2003, 2:427-438.
15. Moreno Reyes R., Egrise D., Nève J., Pasteels J.L., Schoutens A. Selenium deficiency induced growth retardation is associated with an impaired bone metabolism and osteopenia. J. Bone Miner. Res. 2001, 16:1556-1563.
16. Moreno-Reyes R., Mathieu F., Boelaert M., Begaux F., Suetens C., Rivera M.T., Nève J., Perlmutter N., Vanderpas J. Selenium and iodine supplementation of rural Tibetan children affected by Kashin-Beck osteoarthropathy. Am. J. Clin. Nutr. 2003, 78:137-144.
17. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A., Von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol. 2000, 18:3758-3767.
18. Perez E.A., Josse R.G., Pritchard K.I., Ingle J.N., Martino S., Findlay B.P., Shenkier T.N., Tozer R.G., Palmer M.J., Shepherd L.E. Effect of letrozole versus placebo on bone mineral density in women completing 5years (yrs) of adjuvant tamoxifen: NCIC CTG MA. 17b. Breast Cancer Res. Treat. 2004, 88:S36.
19. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., Widmer A., Devogelaer J.P., Kaufman J.M., Jaeger P. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2002, 346:653-661.
20. Robling A.G., Castillo A.B., Turner C.H. Biomechanical and molecular regulation of bone remodeling. Annu. Rev. Biomed. Eng. 2006, 8:455-498.
21. Sadlonova V., Kubatka P., Kajo K., Ostatnikova D., Nosalova G., Adamicova K., Sadlonova J. Side effects of anastrozole in the experimental pre-menopausal mammary carcinogenesis. Neoplasma 2009, 56:124-129.
22. Sasano H., Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr. Rev. 1998, 19:593-607.
23. Thorsen T., Tangen M., Stoa K.F. Concentration of endogenous oestradiol as related to oestradiol receptor sites in breast tumor cytosol. Eur. J. Cancer Clin. Oncol. 1982, 18:333-337.
24. Thürlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Rabaglio M. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005, 353:2747-2757.
25. Turner K.J., Morley M., Atanassova N., Swanston I.D., Sharpe R.M. Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J. Endocrinol. 2000, 164:225-238.
26. Vanderschueren D., Vandenput L., Boonen S., Lindberg M.K., Bouillon R., Ohlsson C. Androgens and bone. Endocr. Rev. 2004, 25:389-425.
27. Vekariya K.K., Kaur J., Tikoo K. ER-α signaling imparts chemotherapeutic selectivity to selenium nanoparticles in breast cancer. Nanomedicine: NBM 2012, 8:1125-1132.
28. Young D.S., Thomas D.W., Friedman R.B., Pestaner L.C. Bibliography: drug interferences with clinical laboratory tests. Clin. Chem. 1972, 18:1041-1304.